Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling

Cancers

Alberto Izzotti¹  Marta Geretto¹  Emilio Di Maria²  Sara Schenone²  FilippoGrillo Ruggieri³  Chiara Ceccaroli⁴ 

[1] Department of Experimental Medicine, University of Genova, 16132 Genova, Italy;Department of Health Sciences, University of Genova, 16132 Genova, Italy;Department of Radiotherapy, Galliera Hospital-Via, 16128 Genoa, Italy;IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy;

关键词: colorectal neoplasms;    neoadjuvant therapy;    biomarkers;    microRNA;    miRNAs;    RNA;   

DOI  :  10.3390/cancers12061652

来源: DOAJ

【 摘 要 】

Colorectal cancer patients’ responses to neoadjuvant therapy undergo broad inter-individual variations. The aim of this systematic review is to identify a molecular signature that is predictive of colon cancer downstaging and/or downgrading after neoadjuvant therapy. Among the hundreds analysed in the available studies, only 19 messenger-RNAs (mRNAs) and six micro-RNAs (miRNAs) were differentially expressed in responders versus non-responders in two or more independent studies. Therefore, a mRNA/miRNA signature can be designed accordingly, with limitations caused by the retrospective nature of these studies, the heterogeneity in study designs and the downgrading/downstaging assessment criteria. This signature can be proposed to tailor neoadjuvant therapy regimens on an individual basis.

【 授权许可】

Unknown